Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5415687 | 0.84 | PKM (0.85) | PKMMEN1KMT2AMAPTJAK2 | |
| SCHEMBL2984938 | 0.82 | PKM (0.82) | PKMMEN1KMT2AMAPTJAK2 | |
| SCHEMBL12092977 | 0.79 | PKM (0.83) | PKMMEN1KMT2AMAPTJAK2 | |
| SCHEMBL4699729 | 0.79 | PKM (0.77) | PKMMEN1KMT2AMAPTJAK2 | |
| SCHEMBL16940 | 0.79 | PKM (0.77) | PKMMEN1KMT2AMAPTJAK2 | |
| SCHEMBL12656171 | 0.79 | PKM (0.77) | PKMMEN1KMT2AMAPTJAK2 | |
| SCHEMBL31553468 | 0.79 | PKM (0.52) | PKMMEN1KMT2AMAPTJAK2 | |
| Hydrochloric Acid SCHEMBL16597 | 0.78 | PKM (0.74) | PKMMEN1KMT2AMAPTJAK2 | |
| SCHEMBL13598990 | 0.77 | PKM (0.72) | PKMMEN1KMT2ANPC1RAB9A | |
| SCHEMBL26105920 | 0.77 | PKM (0.72) | PKMMEN1KMT2AMAPTJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105531268-B | Noval chemical compound and its pharmaceutical composition for treating cystic fibrosis | 加拉佩格斯股份有限公司 | 2017-09-12 | — | — | CN | disclosed |
| US-7041684-B2 | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050043337-A1 | Selective beta3 adrenergic agonists | RITO CHRISTOPHER J (US) | 2005-02-24 | — | — | US | disclosed |
| EP-1063235-B1 | BENZOFURYLPYRONE DERIVATIVES | TEIJIN LTD (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-20030186976-A1 | Benzofurylpyrone derivatives | TEIJIN LIMITED, MICROBIAL CHEMISTRY RESEARCH FOUNDATION | 2003-10-02 | — | — | US | disclosed |
| US-6589984-B1 | Blood cholesterol and triglycerides (TG) themselves are generally insoluble in blood, and they exist as lipoproteins by binding with apolipoproteins. In the body, triglycerides are biosynthesized primarily in the liver from acetyl CoA as | TEIJIN LIMITED (JP) | 2003-07-08 | — | — | US | disclosed |
| US-6413991-B1 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2002-07-02 | — | — | US | disclosed |
| EP-1063235-A1 | BENZOFURYLPYRONE DERIVATIVES | TEIJIN LIMITED (JP) | 2000-12-27 | — | — | EP | disclosed |
| US-6140352-A | FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| US-6093735-A | TREATMENT OF TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| US-6075040-A | OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2000-06-13 | — | — | US | disclosed |
| US-6060492-A | SIDE EFFECT REDUCTION | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186976-A1 | Benzofurylpyrone derivatives | PLIN5, ACSL5, PLIN1 | PKM 2135/4885MEN1 3634/4885KMT2A 4009/4885 |
| US-20050043337-A1 | Selective beta3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | PKM 3300/4885MEN1 4015/4885KMT2A 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.